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ABSTRACT Speech impairment in Parkinson’s Disease (PD) has been extensively studied. Our 
understanding of speech in people who are at an increased risk of developing PD is, however, rather limited. 
It is known that isolated Rapid Eye Movement (REM) sleep Behavior Disorder (RBD) is associated with a 
high risk of developing PD. The aim of this study is to investigate smartphone speech testing to: (1) 
distinguish participants with RBD from controls and PD, and (2) predict a range of self- or researcher-
administered clinical scores that quantify participants’ motor symptoms, cognition, daytime sleepiness, 
depression, and the overall state of health. The rationale of our analyses is to test an initial hypothesis that 
speech can be used to detect and quantify the symptoms associated with RBD and PD. We analyzed 4242 
smartphone voice recordings collected in clinic and at home from 92 Controls, 112 RBD and 335 PD 
participants. We used acoustic signal analysis and machine learning, employing 337 features that quantify 
different properties of speech impairment. Using a leave-one-subject-out cross-validation scheme, we were 
able to distinguish RBD from controls (sensitivity 60.7%, specificity 69.6%) and RBD from PD participants 
(sensitivity 74.9%, specificity 73.2%), and predict clinical assessments with clinically useful accuracy. These 
promising findings warrant further investigation in using speech as a digital biomarker for PD and RBD to 
facilitate intervention in the early and prodromal stages of PD. 
INDEX TERMS Digital biomarkers, Parkinson’s disease, REM sleep behavior disorder, speech analysis, 
statistical learning, smartphones, telemedicine.  
I. INTRODUCTION 
Neurological disorders pose an increasing burden to health 
systems worldwide as leading sources of disability [1]. 
Parkinson’s Disease (PD) is characterized by a range of 
progressively debilitating motor symptoms (including 
bradykinesia, tremor, rigidity) and non-motor (e.g. cognitive, 
neuropsychiatric, autonomic, sleep) symptoms [2]. Speech 
performance degradation is reported in the vast majority of 
people diagnosed with PD and speech-related problems are 
strongly associated with overall PD symptom severity [3], [4].   
There is currently no known cure for PD, however, 
pharmacological and surgical treatment can to some extent 
alleviate the symptoms and improve quality of life for most 
People with PD (PWP) [5]. Regular monitoring of symptom 
progression is indicated to optimize treatment regimens, 
which has relied on expert-based clinical assessments and 
PWP’s self-reports. Clinical assessment relies on established 
validated instruments (rating scales). One of the most widely 
used instruments is the Movement Disorder Society (MDS)-
sponsored revision of the Unified Parkinson's Disease Rating 
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Scale (MDS-UPDRS) [2], which requires skilled expert raters 
to administer. Even though this is well standardized and rater 
training is administered, similarly to other expert-rated scales 
the MDS-UPDRS is known to be prone to inter-rater 
variability [6]. Additionally, the time required to administer 
the MDS-UPDRS often prohibits its routine clinical use. 
Expert administered clinical assessments provide a clinical 
impression of symptom severity and are well-suited for non-
motor and motor-tasks that are more amenable to objective 
external assessment. However, it is crucial to consider the 
PWP’s self-perception of symptom severity, since ultimately 
different PWP have different needs [1]. The proliferation of 
smartphones and smartphone apps has facilitated longitudinal 
collection of Patient Reported Outcome Measures (PROMs) 
for participant symptom self-reporting [7]–[9]. This further 
motivates the need to use PROMs for PD management and 
monitoring of the diverse range of PD symptoms. 
In addition to clinically validated rating scales (expert-based 
assessments and PROMs), the research community has 
embraced the use of technology in the hope of facilitating 
objective, sensor-based PD assessments [10]. These 
developments include the use of wearable sensors [11] and 
smartphones [12]–[14]. We have previously demonstrated the 
use of sustained vowel “aaah” towards: (i) very accurate 
binary differentiation of a matched control group versus PWP 
[15]; (ii) replication of MDS-UPDRS with greater accuracy 
than the inter-rater variability [3], [16]–[18]; (iii) automatic 
assessment of PD voice rehabilitation using the Lee Silverman 
Voice Treatment (LSVT) [19]; (iv) distinguishing people with 
genetic PD predisposition (Leucine-Rich Repeat Kinase 2 
(LRRK2) mutations [20]), PWP, and matched controls; and 
(v) using a large database of voice recordings collected over a 
standard telephone network (sampling frequency 8 KHz) to 
distinguish PWP from age- and sex-matched controls [21]. 
Voice abnormalities have been reported to precede the onset 
of motor symptoms in PD [22]. Investigating the nature and 
extent of vocal impairment in individuals who are at risk of 
developing PD can provide a crucial opportunity to intervene 
in the prodromal stages of the disease and facilitate potential 
recruitment of participants for neuroprotective treatment trials 
aimed at slowing down or preventing conversion to PD. Rapid 
Eye Movement (REM) sleep Behavior Disorder (RBD) is 
among the strongest known predictors of PD risk [23]. Isolated 
RBD is associated with high rates of phenoconversion to a 
neurodegenerative disorder, including PD, dementia with 
Lewy bodies, and multiple system atrophy [24]. Isolated RBD 
is a parasomnia that is typically characterized by dream 
enactments and excess muscle tone during REM sleep [25]–
[27]. Age and sex are the two most common risk factors 
associated with RBD, whereby there is a higher 
preponderance in males. The risk of developing a 
neurodegenerative syndrome, from the time of RBD 
diagnosis, is estimated to be 33.1 at five years, 75.5% at ten 
years, and 90.9% at 14 years, with a median conversion time 
of 7.5 years [24]. The aforementioned reasons motivated our 
decision to investigate the signs and extent of potential vocal 
impairment in participants with isolated RBD. 
For the assessment of RBD, a screening questionnaire is 
sometimes employed (REM Sleep Behavior Disorder 
Screening Questionnaire (RBDSQ)), and the gold standard for 
RBD diagnosis is a polysomnography (PSG) test. 
Administering full PSG incurs substantial logistical costs for 
the healthcare service providers (as the participants need to be 
admitted and monitored throughout the night at hospital). The 
average cost of an overnight PSG test is estimated to be around 
USD 800 [28]. Voice analysis offers the exciting possibility to 
risk stratify individuals and prioritize those who are most 
likely to benefit from a PSG investigation.   
The literature on investigating vocal impairment in 
individuals with RBD is rather scarce. Using speech 
recordings (sustained phonation, syllable repetition and 
monologue) from 16 RBD and 16 age- and sex-matched 
healthy controls, a sensitivity of 96% and specificity of 79% 
has been reported [29]. Using 50 RBD, 30 PD and 30 healthy 
controls, an Area Under the Curve (AUC) value of 0.69 
(sensitivity 69.8%, specificity 64.7%) was achieved in 
discriminating RBD and controls using smartphone-based 
speech, and a high correlation and reliability were found 
between acoustic measures extracted from a professional 
microphone and smartphone [30]. These findings suggest that 
recordings collected from smartphones and professional 
microphones could be of comparable quality. Using the 
speech dataset employed by Rusz et al. [30], a classification of 
up to 66% between early PD and RBD was reported by Benba 
et al. [31]. However, these studies on speech-RBD have 
mainly relied on high-quality recordings, collected in a 
laboratory under controlled acoustic conditions, using small 
cohorts (typically fewer than 50 participants). Thus, current 
studies may be rather limited in drawing inferences and 
scaling findings for screening people with isolated RBD. 
Moreover, in the absence of detailed clinical measures of key 
interest, studies thus far have been unable to offer new insights 
into the relationship between the extent of speech impairment 
and severity of symptoms in RBD.  
The aim of this study is to utilize smartphone speech 
assessments to make the following three main contributions: 
(1) differentiating cohorts of healthy controls (𝑛 = 92), isolated 
RBD (𝑛 = 112), and PD (𝑛 = 335) participants using sustained 
vowel phonations; (2) predicting diverse self- or researcher-
rated established validated clinical metrics assessing symptom 
severity from a deeply phenotyped cohort; (3) highlighting the 
benefits of deep clinical phenotyping to fully maximize the 
application of smartphone speech evaluation for RBD and PD. 
We aim to provide an overview of symptoms in RBD and 
early PD by bridging objective data collected using 
smartphones (voice), clinical ratings (e.g., MDS-UPDRS), 
and self-reports, with the ultimate aim of contributing towards 
the development of a decision support tool for RBD and PD. 
The motor symptoms associated with RBD are subtle, which 
makes it challenging to detect and monitor granular changes. 
                                                     Arora et al.: SMARTPHONE SPEECH TESTING FOR SYMPTOM ASSESSMENT IN RBD and PD  
3 
 
Our analysis is aimed at testing an initial hypothesis that 
acoustic analysis of speech signals can be used to detect and 
quantify the symptoms associated with RBD and PD. This is 
relevant as the objective quantification of symptom severity 
using voice can potentially help identify and prioritize 
participants for PSG, and facilitate intervention in the 
prodromal stage of PD. The novelty of our work lies in 
assessing the relationship between speech impairment and 
symptom severity in isolated RBD, with a focus on motor 
symptoms, cognition, daytime sleepiness, depression, and the 
overall state of health. To the best of our knowledge, this is the 
largest dataset of smartphone-based voice recordings collected 
from a deeply phenotyped RBD cohort. 
The paper is organized as follows. Section II presents the 
study design and clinical data. Section III describes the 
methodology focusing on voice segmentation, feature 
extraction and selection, statistical mapping, and model 
validation. Section IV presents out-of-sample results for 
discriminating the three groups (Controls, RBD, and PD) and 
predicting PROMs and clinician-rated scores. Conclusions are 
presented in Section V, and limitations of this study and plans 
for future work are discussed in Section VI. 
 
II. DATA 
Voice recordings and clinical data were collected from 
participants enrolled in the Oxford Discovery Cohort (further 
details are discussed in Barber et al. [32]; Baig et al. [33]; Lo 
et al. [13]). PWP met the United Kingdom PD Brain Bank 
criteria for probable PD [34]. We included PWP for whom the 
probability of PD was at least 90% (as ascertained by a trained 
researcher) at their most recent clinic visit.  Participants with 
isolated RBD were included if their PSG provided evidence 
supportive of their clinical diagnosis, in keeping with the 
International Classification of Sleep Disorders criteria [35]. 
The study was prospectively approved by the local UK 
National Health Service Ethics research ethics committee 
(10/H0505/71 and 16/SC/0108), in adherence with national 
legislation and the Declaration of Helsinki. All participants 
provided written informed consent before any study-related 
procedures. 
We used data from a cohort of 539 participants, comprising 
92 Controls, 112 RBD, and 335 PWP. Participants were 
provided smartphones installed with a fully customized 
smartphone application that enabled the recording of a range 
of diverse modalities including voice, gait, balance, dexterity, 
reaction time, rest tremor, and postural tremor [12]. We 
focused only on the voice task in this study, for which the 
participants were provided with the instruction: “Hold the 
phone to your ear, take a deep breath, and say ‘aaah’ at a 
comfortable and steady, tone and level, for as long as you 
can.” The sustained vowel phonations “aaah” (International 
phonetic alphabet /a:/) were sampled at 44.1 kHz directly at 
the smartphone, and the recordings were encrypted, 
timestamped, and uploaded to a secure online database.  
During their in-clinic visit, in conjunction with clinical 
assessments, participants performed the voice task under the 
supervision of a trained researcher. Moreover, participants 
were encouraged to take the smartphones home to perform the 
voice task up to four times a day, for seven days. The duration 
of each voice task was 20 seconds. Smartphone data collected 
during the first clinic visit and subsequent home recordings 
(performed within three months of their clinic visit) were used 
for analysis. Our findings are thus not dependent on the voice 
task being performed by participants under supervision in 
clinic. In total, we identified 4242 phonations (𝑛𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠  = 
688, 𝑛𝑅𝐵𝐷  = 1359, 𝑛𝑃𝐷 = 2195) from participants that fulfilled 
the above inclusion criteria.  
Along with speech, we collected various established 
clinically validated metrics that are either expert rater-based or 
PROMs-based, including the MDS-UPDRS (we report both 
the motor MDS-UPDRS (part III, motor examination) and the 
total MDS-UPDRS), Montreal cognitive assessment, Epworth 
sleepiness scale, Beck depression inventory, and visual 
analogue scale (details for each outlined below). In all cases, 
the clinical assessment and the self-reports were collected in 
addition to the speech data. Basic demographics and 
participant information are summarized in Table I. 
 
TABLE I 








Age (years) 68.5 ± 13.2 68.4 ± 12.1 69.5 ± 13.3 
Gender (male/female) 73/19 97/15 206/129 









Years since PD diagnosis 
and smartphone assessment 
 
N/A N/A 3.93 ± 2.2 
Motor MDS-UPDRS  2.0 ± 3.0 
*(𝑛=54) 
5.0 ± 6.0 28.0 ± 17.0 
Total MDS-UPDRS I-III 7.0 ± 7.0 
*(𝑛=30) 
16.0 ± 12.0 49.0 ± 26.0 
MoCA 27.0 ± 3.0 
*(𝑛=50) 
26.0 ± 3.0 26.0 ± 5.0 
ESS 5.0 ± 5.0 
*(𝑛=51) 
6.0 ± 7.0 7.0 ± 6.8 
BDI 2.0 ± 5.5 
*(𝑛=51) 
8.0 ± 12.0 
*(𝑛=109) 
8.0 ± 8.0 
*(𝑛=327) 
EQ-5D-3L VAS 85.0 ± 10.0 
*(𝑛=50) 
80.0 ± 20.0 
*(𝑛=111) 
70.0 ± 20.0 
*(𝑛=332) 
RBDSQ N/A 10.0 ± 3.0 N/A 
Summary statistics are presented in the form median ± interquartile range. 
Abbreviations used: RBD, rapid eye movement sleep behaviour disorder; 
PD, Parkinson’s disease; MDS-UPDRS, Movement Disorder Society 
(MDS)-sponsored revision of the Unified Parkinson’s disease rating scale; 
MoCA, Montreal cognitive assessment; ESS, Epworth sleepiness scale; 
BDI, Beck depression inventory; VAS, Visual analogue scale; RBDSQ, 
RBD screening questionnaire. We have included the number of participants 
(n) for the cases as we do not have entries for all participants in that group. 
A. MDS-UPDRS 
The  MDS-UPDRS is one of the most widely used measures 
to quantify the severity of PD [2]. In this study, we use the 
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motor MDS-UPDRS (the third subscale of the MDS-UPDRS, 
which is also referred to as MDS-UPDRS part III) and the total 
MDS-UPDRS, which constitutes of the following four 
subscales: (I) nonmotor elements of PD, (II) nonmotor 
experiences of daily living, (III) motor examination, and (IV) 
motor complications. The motor MDS-UPDRS is 
administered by a clinician and focuses on assessing the 
severity of motor symptoms. It comprises 33-items, whereby 
each item is scored using the following points scheme: normal 
(0), slight (1), mild (2), moderate (3), and severe (4). The 
maximum value of the motor MDS-UPDRS is 132 points, and 
a higher score represents more severe impairment. For the 
Discovery cohort, part (IV) of the MDS-UPDRS was 
administered only for the PD cohort. In this study, the total 
MDS-UPDRS was computed as the sum of the first three 
subscales (which we refer to as total MDS-UPDRS I-III). 
B. MoCA 
The Montreal Cognitive Assessment (MoCA) is a brief 10-
minute screening test, which exhibits high sensitivity and 
specificity in detecting the signs of Mild Cognitive 
Impairment (MCI), which is a clinical state that may evolve to 
dementia [36]. The MoCA is a 30-point test that evaluates: 
short-term memory recall, visuospatial abilities, multiple 
aspects of executive functions, attention, concentration, 
working memory, language, and orientation to time and place. 
A lower score is associated with a higher likelihood of MCI. 
We used the total MoCA score that was adjusted for education, 
whereby participants with ≤ 12 years of education were 
assigned an additional MoCA point [37].  
C. ESS 
The Epworth Sleepiness Scale (ESS) is a PROMs-based 
questionnaire that assesses ‘daytime sleepiness’ [38]. The test 
comprises 8-items, each rated on a 4-point scale (with 0 
denoting ‘would never doze’ and 3 denoting ‘high chance of 
dozing’), and the total ESS has a range of 0–24.  
D. BDI 
The Beck Depression Inventory (BDI) is a patient self-
reported test that is used to measure the symptoms and severity 
of depression in persons aged ≥ 13 years. The BDI was 
introduced in 1961 and has since undergone multiple revisions 
[39]. In this study, we use BDI-II, which is a 21-item multiple-
choice inventory, in which each item is rated out on a 4-point 
scale (0 to 3, where 3 indicates an extreme form of each 
symptom) [40]. The total BDI-II score has a range of 0 to 63, 
and the interpretation of this score is based on the following 
guidelines: minimal range (0–13), mild depression (14–19), 
moderate depression (20–28), and severe depression (29–63).  
E. EQ-5D-3L VAS 
The Visual Analogue Scale (VAS) is a self-reported test used 
to measure the participants’ health status on the day of the 
interview [41]. Participants were asked to mark their health 
status on a vertical scale, whereby the ‘Worst imaginable 
health state’ corresponds to a score of 0 and ‘Best imaginable 
health state’ equates to a score of 100.  
F. RBDSQ 
The RBD Screening Questionnaire (RBDSQ) is a PROMs-
based instrument which is based on a 10-item questionnaire 
(with each response being either ‘yes’ or ‘no’) [42]. The range 
is 0 to 13 points, where a higher score is associated with a 
higher likelihood of clinical RBD. RBDSQ assesses sleep 
behavior, focusing on a range of different nocturnal aspects, 
including frequency and content of dreams, nocturnal motor 
behavior, injuries, nocturnal awakenings, disturbed sleep, and 
presence of any neurological disorder. Using a cut-off of 5 
points (as a positive diagnosis of RBD), a sensitivity of 96% 
and a specificity of 56% in discriminating RBD versus 
controls has been reported [42]. 
 
III. METHODS 
Our methodology is aimed at characterizing each sustained 
vowel phonation to extract informative acoustic measures 
(also referred to as features), determining a robust feature 
subset using feature selection algorithms, and mapping the 
selected feature subset onto the clinical outcomes of interest. 
A schematic diagram illustrating the different key stages of 
our modeling framework is provided in Fig. 1.  
FIGURE 1. Schematic diagram illustrating the acquisition of the clinical 
and voice data, and major steps involved in the analyses. 
 
Following the confirmation of study group 
(Control/RBD/PD), quantification of symptom severity (using 
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the clinical scores) and vocal assessment, as shown in Fig. 1 
(step A), the first step of our analyses undertook voice 
segmentation, which was aimed at identifying the voice 
segment that corresponds to the sustained vowel phonation 
from the complete duration of the voice recording (step B in 
Fig. 1). Using the segmented phonation, we performed feature 
extraction, which was aimed at characterizing different 
acoustic measures of the signal (step C in Fig. 1). The feature 
matrix (and corresponding labels) were split into training data 
and testing data using a leave-one-subject-out cross-validation 
scheme, whereby all recordings except recordings from one 
participant were used for training the model and for 
identifying the most salient set of features, i.e., feature 
selection (step D in Fig. 1). The process was repeated, 
iteratively leaving the recordings from each participant out. 
We then performed statistical mapping to establish the 
relationship between the input features and the target label, 
whereby using the trained model, predictions were generated 
for the test dataset (one-by-one, for all participants) and the 
model accuracy was validated using a performance score (step 
E in Fig. 1). We now describe the different steps of our 
methodology in more detail below. 
A. Voice segmentation  
Compared to supervised laboratory collected recordings, data 
acquired under non-controlled, free-living conditions yields 
findings that are more scalable to the real-world environment. 
Collecting data under non-controlled settings can, however, 
give rise to data quality issues, such as background noise, 
unexpected user behaviors, etc., which can potentially reduce 
the interpretability and reliability of the analysis. To tackle this 
issue, we developed an automated voice segmentation 
algorithm to identify the most stable single 2-second segment 
of sustained phonation from the voice recordings. The 
segmentation was based on the analysis of changes in 
fundamental frequency over different parts of the voice signal. 
The fundamental frequency (F0) of the speech signals was 
computed using the Sawtooth Waveform Inspired Pitch 
Estimator (SWIPE) algorithm [43], which we had previously 
demonstrated to be the most accurate F0 estimation algorithm 
in sustained vowel /a:/ signals [44]. 
B. Feature extraction 
We characterized each sustained vowel /a:/ phonation using 
custom-built signal processing algorithms to compute 337 
acoustic measures. We have developed a toolkit containing 
known and novel acoustic measures which we have refined 
over the years, specifically for processing sustained vowel /a:/ 
phonations [3], [16], [45], [46]. Briefly, these acoustic 
measures aimed to quantify the deviation from vocal fold 
periodicity (in terms of frequency the jitter variants and in 
terms of amplitude the shimmer variants), acoustic/turbulent 
noise, and articulator placement. For the physiological 
background, rationale, and detailed algorithmic expressions 
for the computation of the acoustic measures please refer to 
our previous studies [6], [13-15]. The MATLAB source code 
for the computation of the acoustic measures is freely 
available on the author’s (AT) website: https://www.darth-
group.com/software. Applying the speech signal processing 
algorithms to the study cohort gave rise to a 4242×337 feature 
matrix. These acoustic measures are summarized in Table II, 
whereas Table III for convenience summarizes the key 
acoustic aspects we aim to quantify using algorithmic 
processing and the corresponding acoustic measures. We 
remark there are different approaches to categorizing the 
acoustic measures, and the proposed approach serves as a 
useful methodological summary perspective. Also note that 
some acoustic measures to a certain extent, quantify aspects of 
more than one of the assigned categories. 
TABLE II 
BREAKDOWN OF THE 337 ACOUSTIC MEASURES USED IN THIS STUDY 






Jitter variants F0 perturbation 21 
Shimmer variants Amplitude perturbation 22 
Harmonics to Noise Ratio 
(HNR) and Noise to 
Harmonics Ratio (NHR) 
Signal to noise, and noise to 
signal ratios 4 
Glottis Quotient (GQ) Vocal fold cycle duration 
changes 
3 
Glottal to Noise 
Excitation (GNE) 
Extent of noise in speech using 
energy and nonlinear energy 
concepts 
6 
Vocal Fold Excitation 
Ratio (VFER) 
Extent of noise in speech using 






Signal to noise ratios using 
EMD-based energy, nonlinear 
energy and entropy 
6 
Mel Frequency Cepstral 
Coefficients (MFCC) 





Amplitude, scale, and 
envelope fluctuations 
quantified using wavelet 
coefficients 
182 
Pitch Period Entropy 
(PPE) 








Density Entropy (RPDE) 
Uncertainty in estimation of 
fundamental frequency 1 
Algorithmic expressions for the 337 acoustic measures summarized here are 
described in detail in [3], [19], [45], [46], [53]. The MATLAB source code 
for the computation of the acoustic measures is freely available on the 
author’s (AT) website: https://www.darth-group.com/software. F0 refers to 
fundamental frequency estimates, here computed using SWIPE [43]. 
C. Feature exploration and statistical analysis 
We explored the data using standard visualization tools in 
the form of violin plots to get a succinct representation of the 
underlying variable distributions. Subsequently, we computed 
correlation coefficients to express the statistical association 
between the acoustic measures and the clinical scales. We 
used the non-parametric Spearman correlation coefficient to 
account for a generic approach which does not require data 
normality, and computed statistical significance at the 95% 
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level (p-values) for the null hypothesis that the acoustic 
measures were not statistically correlated with the clinical 
scales. We considered a relationship to be statistically strong 
when the magnitude of the correlation coefficient R is at least 
0.3, using the empirical rule of thumb in biomedical 
applications [47]. 
TABLE III 
KEY ACOUSTIC ASPECTS AND CORRESPONDING ACOUSTIC MEASURES 
Key acoustic aspect 
quantified 
Acoustic measures used 
Deviations in retaining 
stable F0 and F0 
variability 
Jitter variants, Pitch Period Entropy (PPE), 
Recurrence Period Density Entropy (RPDE), 
Glottis Quotient (GQ), wavelet-based 
coefficients for F0 variability assessment 
Deviations in retaining 
stable amplitude 
Shimmer variants 
Signal to noise ratio, 
quantifying excessive 
level of acoustic noise 
Harmonics to Noise Ratio (HNR) and Noise 
to Harmonics Ratio (NHR), Detrended 
Fluctuation Analysis (DFA), Glottal to Noise 
Excitation (GNE), Vocal Fold Excitation 
Ratio (VFER), Empirical Mode 









Higher MFCCs (and corresponding delta and 
delta-delta MFCCs)  
D. Feature selection 
A well-known problem in practical data analytics is the curse 
of dimensionality: a large number of features increases the 
noise in the dataset and may be detrimental in the statistical 
learning process [48]. Occam’s razor dictates that we should 
aim to determine the most parsimonious statistical model, i.e. 
develop a statistical learning model that is maximally 
predictive with the minimum number of features. There are 
many different strategies to perform Feature Selection (FS); 
for an overview please refer to Guyon et al. [49]. Here, we 
used the importance scores from the Random Forests (RF) 
algorithm (see the following section) to rank the features and 
identify a robust subset. This embedded FS approach has the 
advantage that it is integral to the RF model building process 
alleviating the need for an additional external step towards FS, 
and has shown promising results in diverse applications [50]. 
E. Statistical mapping 
There are many statistical mapping algorithms in the literature, 
and this continues to be an active area of research. Here, we 
used RF [51] following the recommendation of Hastie et al. 
that tree-based ensembles are the best off-the-shelf classifiers 
[48]. A key competitive advantage of RF over some 
competing advanced statistical learning algorithms is that RF 
is very robust to the choice of hyperparameters (number of 
trees and number of features over which to optimize). We used 
the standard settings for these hyperparameters following 
Breiman’s recommendations [51]: 500 trees and the square 
root of the number of features for split point selection at each 
node. Moreover, to tackle class imbalance, the votes cut-off 
for the classes was changed such that the minority class had a 
lower cut-off (directly proportional to the number of 
observations in that class) [52]. 
F. Model performance and validation 
To assess the statistical model performance and investigate its 
performance in unseen data, we used the standard Leave-One-
Subject-Out (LOSO) Cross-Validation (CV) approach. 
Specifically, the statistical learning model was trained using 
the samples of the 𝑁-1 unique participants, and tested on the 
performance of correctly estimating the data for the participant 
that was not used in the training phase. Using LOSO, the 
process of model training and predicting was repeated for a 
total of 𝑁 times (one time for each participant). Using all 𝑁 
labels and corresponding predictions, we report the sensitivity 
and specificity for pairwise discriminations, and the Mean 
Absolute Error (MAE) when referring to estimating the 
clinical scores. The MAE values are summarized in the form 
median ± Interquartile Range (IQR). 
To discriminate the three groups (Controls, RBD and PD), 
using only the features extracted from sustained phonations, 
we performed the following pairwise comparisons: (1) 
Controls versus PD, (2) Controls versus RBD, and (3) RBD 
versus PD. For each pairwise comparison, we employed an 
ensemble of classification trees using: (1) all available 
recordings, (2) only male recordings, and (3) only female 
recordings. Moreover, to investigate the effect of the data size 
on classification accuracy, we performed the analyses using: 
(i) only a single voice recording per participant (first voice 
recording collected from each participant), and (ii) total 
number of recordings contributed by a given participant. Since 
different participants contributed a different number of 
recordings in the testing scenario (ii), we performed model 
validation such that each participant was assigned equal 
weight during the model validation. Specifically, for a given 
participant, we used a majority voting scheme to determine if 
the majority of recordings were classified as belonging to 
either class 1 or class 2, assigning the final estimate to the 
majority class for that participant. This resulted in one label 
and one classification per participant, which was subsequently 
used for assessing the model performance. Additional details 
pertaining to the analyses can be found in [3], [19], [45], [46], 
[53], and references therein.   
IV. RESULTS 
Participants from the three groups were age-matched. Pairwise 
comparisons of age distributions (Controls vs PD, Controls vs 
RBD, and RBD vs PD) rejected the null hypothesis that the 
age distributions were significantly different (using a two-
sided Kolmogorov-Smirnov test with 5% significance level). 
This helps garner confidence that the findings of our study are 
not biased due to the presence of presbyphonia as a potential 
confounding factor. We start our exploration by visualizing 
the underlying distributions of the clinical scales for the three 
cohorts (see Fig. 2). 




FIGURE 2. Violin plots summarizing the distributions of the key clinical 
metrics and comparing the three groups. The boxplot is embedded within 
each violin plot, where the white circle denotes the median and the grey 
box denotes the 25th percentile (lower end) and 75th percentile (upper 
end). The horizontal line within each violin plot denotes the mean. 
Clinical metrics are analysed across the three groups (Controls vs RBD, 
RBD vs PD, and Controls vs PD) using the Mann–Whitney U test. 
Statistically significant findings (𝑝 < 0.05) are marked using *.  
 
The difference in all clinical metrics for the control and PD 
cohorts were found to be statistically significant, while this 
was not the case for MoCA and BDI for the RBD and PD 
cohorts. To account for potential group differences in sex, we 
stratified the data to present the results separately for each 
pairwise group comparison, using all recordings, only female 
recordings, and only male recordings. We next focus on 
investigating the pairwise discrimination of the three cohorts 
using speech signals. Using only a single recording per 
participant (𝑛𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠  = 92, 𝑛𝑅𝐵𝐷 = 112, 𝑛𝑃𝐷 = 335), the out-
of-sample classification accuracy was slightly higher for RBD 
versus PD, compared to the accuracy obtained in 
discriminating Controls vs PD, and Controls versus RBD, as 
shown in Table IV.  
TABLE IV 
DISCRIMINATION ACCURACIES FOR THE 3 PAIRWISE COMPARISONS USING 
THE LEAVE-ONE-RECORDING-OUT CROSS-VALIDATION SCHEME  




 Sensitivity (%) Specificity (%) 
 
Controls vs PD 
 
All 62.1% 56.5% 
Male 61.7% 58.9% 
Female 47.3% 36.8% 
 
Controls vs RBD 
 
All 56.3% 70.7% 
Male 57.7% 69.9% 
Female 40.0% 42.1% 
 
RBD vs PD 
 
All 66.9% 66.1% 
Male 60.7% 70.1% 
Female 59.7% 66.7% 
No. of recordings 𝑛𝐴𝑙𝑙  𝑛𝑀𝑎𝑙𝑒 𝑛𝐹𝑒𝑚𝑎𝑙𝑒 
Controls 92 73 19 
RBD 112 97 15 
PD 335 206 129 
    
We chose the recording corresponding to the first speech test 
performed by each participant in Table IV. For all three 
pairwise comparisons, the accuracy obtained using all 
recordings and only male recordings were rather similar, while 
the accuracy using only female recordings were poor. This can 
be attributed to the fact that both RBD and Control cohorts 
comprised very few female participants, and thus the analyses 
using only female recordings are likely to be less reliable.  
The out-of-sample classification accuracy obtained using the 
total number of available recordings and a majority 
assignment scheme (to assign equal weight to each participant 
during the model validation) is presented in Table V. While 
we were able to distinguish RBD participants from controls 
and PD with decent accuracies (Table V), the discrimination 
accuracy for Controls vs PD, was surprisingly poor. Although 
this requires further investigation, a potential reason for poor 
discrimination accuracy using the control recordings could be 
that compared to the other two cohorts, the number of control 
recordings were about half and one-third of the total number 
of recordings from RBD and PD participants, respectively. 
Moreover, only 39 controls contributed more than one speech 
recording, as opposed to 76 RBD and 126 PD participants who 
performed multiple speech tests.  
In terms of discriminating Controls vs RBD, the results of 
this study (as presented in Table V, sensitivity 56.3% and 
specificity 70.7%) are in broad agreement with previous 
findings that were based on a smaller cohort which had 
reported sensitivity 69.8% and specificity 64.7% [30].  
To further explore reasons for the poor discrimination 
accuracy, using all recordings for Controls vs PD, we 
undertook additional analyses employing following schemes 
to alleviate class imbalance issues: class weights, 
undersampling the majority class, and RUSBoost [52], [54]. 
However, the discrimination accuracy was not noticeably 
better using these schemes. 
 
TABLE V 
DISCRIMINATION ACCURACIES FOR THE 3 PAIRWISE COMPARISONS USING 
THE LEAVE-ONE-SUBJECT-OUT CROSS-VALIDATION SCHEME  




 Sensitivity (%) Specificity (%) 
 
 
Controls vs PD 
 
All 59.4% 67.4% 
Male 55.3% 72.6% 
Female 48.1% 36.8% 
 
Controls vs RBD 
 
All 60.7% 69.6% 
Male 59.8% 74.0% 
Female 46.7% 26.3% 
 
RBD vs PD 
 
All 74.9% 73.2% 
Male 74.8% 75.3% 
Female 51.9% 46.7% 
No. of recordings 𝑛𝐴𝑙𝑙 𝑛𝑀𝑎𝑙𝑒  𝑛𝐹𝑒𝑚𝑎𝑙𝑒  
Controls 688 583 105 
RBD 1359 1154 205 
PD 2195 1311 884 
    
 
 





FIGURE 3. Heatmap summarizing the statistical associations for all 
participants across the 337 features with the 6 clinical scales. 
 
 
FIGURE 4. Heatmap summarizing the statistical association for the 
stratified group cohorts across the 337 features with the 6 clinical scales.  
 
Subsequently, we investigated the statistical associations of 
the features with the clinical scales; to keep those concise the 
results are summarized in Fig. 3 for all participants, and then 
in Fig. 4 stratifying the data for the three cohorts. Collectively, 
the findings in Figs. 3 and 4 suggest there are some statistically 
strong associations between the acoustic measures and the 
clinical scales. In Figs. 3 and 4, the magnitude of the Spearman 
correlation coefficients (using only one speech recording per 
participant) was less than 0.5 and hence we have compressed 
the scale presented in the range [-0.5 0.5], whereby the order 
of the 337 features in the heatmap follows the presentation in  
Table II. In a few cases, strong correlations were revealed only 
after stratifying the original dataset into the group cohorts, 
which motivates the need to develop stratified cohort-based 
models to estimate the different clinical scales using speech. 
We defer more detailed elaboration on the most strongly 
associated features with the clinical scales and cross-
comparisons for the Discussion.  
Table VI presents the out-of-sample LOSO results for each 
of the clinical scales for the three cohorts and also for the three 
groups collectively. We have followed the methodology 
outlined above assessing the performance of the classifier both 
when using a single recording per participant, and also all 
available recordings with a majority voting scheme on LOSO 
validation. The results were similar, and here we present only 
the findings with a single recording per participant. 
TABLE VI 












1.0 ± 2.0 2.5 ± 5.0 8.0 ± 9.0 
Total MDS-
UPDRS I-III 
1.0 ± 3.0 6.0 ± 8.0 14.0 ± 18.0 
MoCA 1.0 ± 2.0 2.0 ± 2.0 2.0 ± 3.0 
ESS 2.0 ± 2.0 3.0 ± 4.0 3.0 ± 4.0 
BDI 1.0 ± 4.0 5.0 ± 8.0 4.0 ± 6.0 
VAS 6.5 ± 5.0 10.0 ± 18.0 10.0 ± 15.0 
The out of sample Mean Absolute Error (MAE) performance reported here 
was computed using the leave-one-subject-out cross-validation scheme: this 
corresponds to the MAE between the ground truth and the estimates for each 
individual in the cohort (e.g. we computed 335 entries for PD). 
Subsequently we need to succinctly summarize these MAE entries and here 
we report findings in the form median ± IQR. These results were determined 
by feeding into RF all 337 features and also exploring whether feeding in 
progressively the top 1…25 features resulting from the RF importance 
scores for each sub-problem (indicatively, we illustrate these for motor 
MDS-UPDRS in Fig. 5). 
 
Indicatively, we illustrate in Fig. 5 performance of RF in 
predicting the motor MDS-UPDRS. The out-of-sample model 
performance, as quantified using the MAE, is shown as a 
function of the number of most salient features used during the 
modelling. The order of the presented features was determined 
using the ranked RF importance scores. For brevity, we only 
illustrate the results for motor MDS-UPDRS.  
 
FIGURE 5. LOSO MAE performance of the RF in predicting the motor 
MDS-UPDRS as a function of the number of features presented into the 
classifier. The corresponding symbol in each case indicates the median 
and the bars the IQR.  
 
Finally, for the RBD cohort, we explored how the acoustic 
measures relate to the RBDSQ score. Table VII presents the 
correlation coefficients of the ten most strongly associated 
acoustic measures with the RBDSQ score. Similarly, to the 
preceding analyses, we have aimed to estimate RBDSQ 
presenting the acoustic measures into RF for evaluating the 
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model performance in a LOSO framework. Encouragingly, we 
have found that the RBDSQ can be estimated accurately for 
the RBD cohort (𝑛𝑅𝐵𝐷 = 112) with a LOSO MAE of (median 
± IQR) 1 ± 1 RBDSQ points. 
 
TABLE VII 
CORRELATION COEFFICIENTS OF ACOUSTIC MEASURES WITH RBDSQ  
Acoustic measure Correlation coefficient 
Standard deviation of the 0th delta-delta MFCC 0.260 
VFERmean -0.253 
Average of the 9th delta MFCC 0.248 
VFERentropy -0.244 
Standard deviation of the 3rd MFCC 0.241 
Standard deviation of the 0th MFCC 0.220 
EMD-ERSNR,SEO -0.217 
Standard deviation of the 0th delta MFCC 0.215 
Standard deviation of the 3rd delta-delta MFCC 0.206 
Average of the 7th delta MFCC -0.196 
 We present only the 10 most strongly associated acoustic measures for 
brevity. In all cases the correlations were statistically significant (p<0.05). 
V. CONCLUSIONS 
This study aimed to provide the first comprehensive 
investigation of a diverse range of PD and RBD clinical scales 
when using smartphone-based speech signal analysis. We 
have found that speech can be used to estimate diverse PD and 
RBD clinical scales with reported MAE that would make these 
estimations clinically meaningful. We demonstrated that 
RBDSQ can be estimated very accurately with a MAE of 
(median ± IQR) 1 ± 1 points. Given that RBD is a group that 
may convert to PD and that the RBDSQ quantifies RBD 
symptoms, this finding may have important implications 
towards early assessment of prodromal symptoms in PD prior 
to clinical diagnosis. Moreover, we were able to distinguish 
RBD participants from both controls (sensitivity 60.7%, 
specificity 69.6%) and PD (sensitivity 74.9%, specificity 
73.2%). These results could potentially indicate that the vocal 
deficits in participants with isolated RBD might be different 
than those with PD. These findings warrant longitudinal 
studies to investigate speech impairment in participants with 
RBD. While previous studies have typically focused on 
speech analysis for PD, this study demonstrates that speech 
provides the means towards clinically meaningful insights into 
symptom severity displayed across the spectrum of both PD 
and RBD. These results from a deeply clinically phenotyped 
cohort highlights that speech can potentially be used as a 
digital biomarker for prodromal PD. 
We emphasize that the PD cohort were at the early stages of 
the disease with relatively mild symptoms as summarized in 
MDS-UPDRS (see Table I). Moreover, whilst previous 
speech-RBD studies have employed lab-quality recordings, 
we felt it was imperative to use recordings collected under 
realistic environment settings to address issues regarding 
scalability and generalizability of previous findings. It is for 
this reason that we collected voice recordings under clinic- and 
home-based settings via smartphones, from one of the largest 
cohorts of RBD and PD participants. The data were collected 
by participants themselves using a wide variety of off-the-
shelf consumer-grade smartphones (manufactured by major 
international brands). 
We explored the statistical associations (using Spearman 
correlation coefficients) of 337 features, which have been used 
in similar problems when processing sustained vowel /a:/ 
phonations in PD, with six widely used PD clinical scales (see 
Fig. 3). We confirmed some of our previous findings [3], [16], 
finding statistically strong associations (|R|>0.3) between 
some of the acoustic measures and the MDS-UPDRS (both 
motor MDS-UPDRS and total MDS-UPDRS I-III). 
Interestingly, for some of the clinical scales, we observed that 
statistical correlation became more pronounced in stratified 
groups (see Fig. 4). Further work is needed to verify these 
findings in larger Control, RBD and PD cohorts. 
RF derived feature rankings were sub-problem specific and 
did not generalize across problems (results not shown), 
verifying what could have been expected also when 
visualizing the statistical correlations summarized in Fig. 4. 
This tacitly suggests there are different underlying properties 
quantified by the acoustic measures which were best tailored 
for the estimation of the different clinical scales. Overall, we 
found that a proportion of features from the VFER-family, 
MFCCs and wavelet-based acoustic measures were 
statistically strongly correlated with the clinical scales (Fig. 4) 
and were highly ranked using the RF importance scores. This 
is broadly in agreement with our previous findings in related 
PD applications [3], [19], [21]. 
VI. LIMITATIONS AND FUTURE WORK 
 Despite the promising findings reported herein, there are 
some limitations of this study. Firstly, the quality of voice 
samples collected using smartphones under clinic- and home-
based settings is likely to be of relatively worse quality 
compared to data collected under acoustically highly 
controlled lab-settings (e.g., double-walled sound booths), 
which potentially translates into lower discriminatory 
accuracy for the cohorts investigated. Secondly, this study 
relies on acoustic signal analysis using only one type of 
sustained phonation (“aaah”), which may not adequately 
encapsulate the whole spectrum of speech symptoms in RBD 
and PD. It is plausible that acoustic analysis based on a 
multitude of sustained phonation types, syllable repetition, and 
monologue, may improve the efficacy of the biomarker and 
provide a more complete understanding of the degree of 
speech impairment in PD, such as soft speech (hypophonia), 
monotonous speech with the lack of inflection (aprosody), and 
dysarthria in the form of inability to separate syllables clearly 
(tachyphemia). Thirdly, we collected data from only three 
groups (controls, RBD, and PD), thereby not accounting for 
other parkinsonism and tremor disorders that may also exhibit 
comparable patterns of impairment in speech. Therefore, the 
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extent of our claims on the basis of the available data is 
restricted to the differentiation of the three cohorts. The 
development of a robust, reliable clinical decision support tool 
towards differential diagnosis would require the use of a large 
sample size across a wider range of related neurodegenerative 
disorders. Finally, although we validated our statistical 
framework on an independent test dataset, we used data from 
only one cohort (Discovery cohort). Validation based on an 
external independent cohort would have provided additional 
reliability to these findings. Future studies could address some 
of the aforementioned limitations. An interesting line of future 
work would be to longitudinally monitor speech, along with 
other motor and non-motor symptoms, with a particular focus 
on participants with RBD who eventually convert to an overt 
neurodegenerative disease. We envisage the findings of this 
work would contribute towards the risk stratification of 
individuals who are at the risk of developing PD and assist in 
remote longitudinal monitoring of PD symptoms. Overall, this 
study extends the increasing evidence presented in the 
research literature capitalizing on biomedical speech signal 
processing towards the objective assessment of RBD and PD. 
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